Protagonist Therapeutics (PTGX) said Friday data from phase 1 and preclinical studies showed oral drug candidate JNJ-2113 produced systemic...
Health care stocks were steady premarket Wednesday. The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) were unchanged...
Protagonist Therapeutics (PTGX) said Tuesday it priced its underwritten public offering of 5 million common shares at $20 per share for gross proceeds of...
Protagonist Therapeutics (PTGX) said late Tuesday it launched a $100 million public offering of common shares. The biopharmaceutical company expects to...
| Address | 7707 Gateway Boulevard Newark, California 94560-1160 |
| Phone | +1.510.474.0170 |
| Number of Employees | 64 |
| Recent SEC Filing | 06/02/2023 4 |
| President, Chief Executive Officer & Director | Dinesh V. Patel |
| Chief Financial Officer & Executive Vice President | Asif Ali |
| Chief Technical Officer & Executive VP | Mohammad Masjedizadeh |
| Chief Medical Officer | Arturo Molina |
| Price Open | $29.50 |
| Previous Close | $29.36 |
| 52 Week Range | $6.91 - 29.56 |
| Market Capitalization | $1.7 B |
| Shares Outstanding | 57.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/03/2023 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.83 |
| Beta vs. S&P 500 | N/A |
| Revenue | $30.9 M |
| Net Profit Margin | -16,319.91% |
| Return on Equity | -59.44% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
